title: [The possible options for the prevention of preeclampsia].
abstract: This review summarizes the possible options for the prevention of preeclampsia based on important factors of patomechanism. The effects of antioxidants have been described in numerous clinical researches based on the oxidative hypothesis. Another important factor is the change of nitric oxide activity. Nitric oxide donors are able to compensate the symptoms of preeclampsia. The inverse relationship between the calcium intake and gestational hypertension has been known for a long time. The calcium supplementation seems to be a good opportunity to prevent preeclampsia. With low molecular weight heparins we can intervene in the patomechanisms of preeclampsia by antithrombocyte effects, vasoactive properties and impact on throphoblast cell morphology and differentiation. Thrombocyte aggregation inhibitors were examined in number of studies because they reduced thromboxane mediated vasoconstriction and inhibited placental thrombosis. Several studies verify whether prophylaxis with low molecular weight heparins and low dose aspirin could improve pregnancy outcome in preeclampsia.
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Aneszteziológiai és Intenzív Terápiás Tanszék Debrecen Nagyerdei krt. dofadr@freemail.hu
authors.forename: Andrea
authors.initials: A
authors.lastname: Fodor
authors.forename: András
authors.initials: A
authors.lastname: Gyorffy
authors.forename: Magdolna
authors.initials: M
authors.lastname: Váradi
authors.forename: Béla
authors.initials: B
authors.lastname: Fülesdi
authors.forename: Tamás
authors.initials: T
authors.lastname: Major
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use*; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D002118:Calcium / Q000378:metabolism; D017610:Calcium Compounds / Q000008:administration & dosage*; D019587:Dietary Supplements; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011225:Pre-Eclampsia / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D011247:Pregnancy
chemical_list: D000925:Anticoagulants; D000975:Antioxidants; D017610:Calcium Compounds; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D009569:Nitric Oxide; D001241:Aspirin; D002118:Calcium